Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 542 (miR-542) is a non-coding RNA molecule that regulates gene expression by binding to complementary sequences in messenger RNAs, resulting in translational repression and gene silencing. The most studied forms are miR-542-3p and miR-542-5p. miR-542 plays diverse roles in biological processes such as apoptosis, cell cycle control, cell proliferation, mitochondrial function, and osteoblast differentiation. It acts predominantly as a tumor suppressor in cancer by downregulating oncogenic pathways and is implicated in various signaling cascades, including the Wnt/β-catenin, ERK, JAK2, and PI3K/AKT pathways. miR-542 is also linked to muscle atrophy by promoting mitochondrial dysfunction and increased SMAD2/3 phosphorylation via TGF-β signaling, and it negatively regulates bone formation by targeting bone morphogenetic protein 7 (BMP-7). Aberrant levels of miR-542 contribute to disease progression in cancer, muscle wasting diseases, and bone pathologies, making it a potential biomarker and therapeutic target[1][2][3].
Inhibition of target mRNA translation via RNA interference\nSilencing of specific genes (e.g., SMAD7, BMP-7, MRPS10)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 542 (miR-542).